- Home
- GILD vs MA Comparison
GILD vs MA Comparison
Compare GILD & MA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | MA |
|---|---|---|
| Founded | 1987 | 1966 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.6B | 431.9B |
| IPO Year | 2003 | 2005 |
Fundamental Metrics
Financial Performance| Metric | GILD | MA |
|---|---|---|
| Price | $126.50 | $499.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 26 |
| Target Price | $148.39 | ★ $649.19 |
| AVG Volume (30 Days) | ★ 6.7M | 3.3M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.55% | 0.66% |
| EPS Growth | ★ 1684.21 | 18.93 |
| EPS | 1.61 | ★ 4.35 |
| Revenue | $24,689,000,000.00 | ★ $32,791,000,000.00 |
| Revenue This Year | $4.68 | $16.19 |
| Revenue Next Year | $6.04 | $12.35 |
| P/E Ratio | ★ $77.05 | $112.79 |
| Revenue Growth | 9.98 | ★ 16.42 |
| 52 Week Low | $107.19 | $464.52 |
| 52 Week High | $157.29 | $601.77 |
Technical Indicators
Market Signals| Indicator | GILD | MA |
|---|---|---|
| Relative Strength Index (RSI) | 43.65 | 54.59 |
| Support Level | $116.55 | $487.11 |
| Resistance Level | $126.46 | $529.49 |
| Average True Range (ATR) | 3.62 | 10.21 |
| MACD | -0.34 | 1.39 |
| Stochastic Oscillator | 31.82 | 99.08 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About MA Mastercard Incorporated
Mastercard is the second-largest payment processor in the world, having processed close to $11 trillion in volume during 2025. Mastercard operates in over 200 countries and processes transactions in over 150 currencies.